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Abstract 
New chlorophyll derivatives (pheophytins along with pheophorbide-derivatives) were isolated 
from the leaves of Ficus exasperata and were found to have varying effects on uterine 
contractility. The current study was therefore aimed at the utilization of mass spectrometry and 
nuclear magnetic resonance spectroscopy coupled with isolated uterine tissue assay as a 
platform to assist in the determination of the mechanism of activity of the chlorophyll 
compounds isolated from the plant F. exasperata. The pheophytin and pheophorbide 
compounds were added to the isolated uterine tissues at 200 µg/ml. Mice uteri, treated with the 
pheophytin compounds, and the physiological buffer in which the uterine tissues were 
immersed, were rapidly collected then analyzed using HRFTMS and proton (1H)-NMR for 
bioinformatics study. Resulting data were analyzed via pair-wise chemometric comparison 
models, with P < 0.05 considered statistically significant. Primary signaling pathways found to 
be correlated with the pheophytins in this study included cAMP, dopamine, extracellular 
signal-regulated kinases 1/2 and glutamate pathways.  
Keywords: Pharmacology; Metabolomics; Uterus: Pheophytin; Chlorophyll 
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Introduction 
New chlorophyll derivatives (pheophytins along with pheophorbide-a derivatives) were 
isolated from the leaves of F. exasperata and were found to have varying effects on uterine 
contractility. These new pheophytins included; compound 31: ethyl 3- docosa-4,6,8-trien-1-yl]-
16-ethenyl-3-hydroperoxypentamethyl-4-oxo-7,23,24,25-tetraazahexacyclo-
hexacosapropanoate (ficusphytin-a1); compound 41: ethyl 3-16-ethenyl-3-hydroperoxy-
3,11,12,17,21,26-hexamethyl-4-oxo-7,23,24,25-tetraazahexacyclohexacosapropanoate 
(ficusphytin-a2); compounds 71: (1E)-but-1-en-1-yl 3-[(21S)-16-ethenyl-3-hydroperoxy-12- 
pentamethyl-4-oxo-7,23,24,25-tetraazahexacyclohexacosapropanoate (ficusphorbide±b1);  
compound 81: (1E,3E)-henicosa-1,3-dien-1-yl-3-[(21S)-16-ethenyl-3-hydroperoxy-12- 
pentamethyl-4-oxo-7,23,24,25-tetraazahexacyclohexacosapropanoate (ficusphorbide±b2); and 
compound 91: methyl 3-[(21S)-16-ethenyl-3-hydroperoxy-12-pentamethyl-4-oxo-7,23,24,25-
tetraazahexacyclo hexacosapropanoate (ficusphorbide±b3). Apart from the new pheophytins, 
pheophorbide-a and pyropheophorbide-a were also isolated from the leaves of F. exasperata1.  
In our previous study, pheophorbide-a derivatives at concentrations of 70 ± 200 µg/ml, 
were mainly observed to reduce the amplitude but increase the frequency of uterine 
contractions1, this was similarly observed in fraction 6-17 (C3-5). However, fraction 4-31 
(C6) inhibited uterine contractions1. The short chain pheophorbide-b derivatives exerted both 
a stimulatory and inhibitory effect on spontaneous uterine contractions while inhibiting 
oxytocin-induced uterine contractions1. Due to low available yields of the compounds at the 
stage of structure elucidation, it was impossible to continue with further characterization of the 
uterine activities of the compounds. Metabolomic investigation was therefore performed to 
enable characterization of activities due to the low quantities available. Metabolomics which 
involve the use of high resolution Fourier transform mass spectrometry (HRFTMS) and 
1D/2D- nuclear magnetic resonance (NMR) enabled the study of changes in metabolomic 
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profile, which are produced by living tissues2,3. Metabolites have been described as functional 
units within cells, which are released in response to signals or stimuli. Measurement of these 
metabolites therefore can assist in the understanding of basic and underlying mechanisms 
related to metabolic actions4. Biofluids and/or tissues  can be sampled for metabolomic analysis 
measurement and in such instances these samples can be used to investigate specific 
information associated with the tissue or organ while the study of  biofluids can provide a 
projection of the metabolic changes that have occurred within organs or tissues5. 
This study was therefore aimed at the use of metabolomic techniques coupled with 
functional ex vivo uterine assay as a platform to determine fluxes in metabolite profiles during 
treatment with pheophytins isolated from F. exasperata. Knowledge of these changes in 
metabolomics profiles can provide more information into the mechanism(s) of activity of the 
chlorophyll derivatives on uterine contractility. 
 
Materials and Methods 
Animals 
Female C57BL/6 strain laboratory mice weighing between 20-30 g, obtained from the 
Biological Procedures Unit of the University of Strathclyde, U.K. were used in this study. The 
animals were maintained in a controlled environment and in an air-conditioned room at 25°C, 
60% relative humidity under a 12/12h cycle of light and dark with free access to food and 
water. 
All experiments were carried out in accordance with the Animal Health and Welfare 
(Scotland) Act 2006 and the Public Health Service Policy on Humane Care and Use of 
Laboratory Animals 2002. Mice were euthanized under rising concentration of CO2 and 
exsanguinated before excision of the uterine tissues.  
5 
 
Contractility Experiments 
Methods described previously by Bafor and colleagues were employed1. Briefly, mice in pro-
estrous and estrous stages were used. Contractility experiments were performed on the 
dissected uteri, which were cut into segments of approximately 0.5 - 0.8 cm in longitudinal 
length, cleaned of extra connective tissues to provide four preparations per mouse. The 
segments were then weighed and subsequently mounted in warmed (37 °C) 3 ml organ baths 
containing normal Krebs-Henseleit physiological solution which was composed of 118.4 NaCl, 
25 NaHCO3, 11.1 Glucose, 4.69 KCl, 2.41 MgSO4, 1.18 KH2PO4, 2.5 CaCl2 (mM) and 
continuously gassed with carbogen (95% O2, 5% CO2). Tissues were set up with an initial 
tension of 1 g and equilibrated for 30 min before the start of the experiments. The force and 
frequency of spontaneous contractions in the longitudinal muscle layer were recorded through 
Grass (FTO3) isometric force transducers connected via Quad Bridge modules to a PowerLab 
4/20 data acquisition system using Chart 3.3 software (AD Instruments, UK) which was used 
to store and analyze acquired data. 
Concentration-Response Studies 
Single concentrations (200 µg/ml) of C3-5 which were eluted as a mixture (ficusphytin-a1 and 
a2, and pheophytin-a) or C6 (pyropheophorbide-a), were added to the bath for 10 min 
following stable rhythmic spontaneous contractions. This concentration was selected as the 
maximum concentration for observation of activity based on the previous study. Single 
concentrations are preferred in metabolomic studies as it saves cost and ensures precise 
correlations of activity with the concentration involved. Without washing and while the 
compounds were still in the organ bath, the uterine tissues were rapidly collected after 10 min, 
placed into pre-weighed cryovials and immersed in liquid nitrogen for 20 s. This was done in 
order to snap freeze the tissues and keep the internal environment of the metabolites in the 
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tissues intact. Snap freezing is critical for experiments where it is necessary to retain the activity 
within a biological sample at a specified period, as it prevents the cells responding to any 
handling perturbation6.  Bath fluids where the tissues were immersed, were similarly collected 
(3 ml) and snap frozen. All samples were subsequently stored at í80 °C prior to further 
experiments. Four (4) animals each for individual experiments were employed. All graphs were 
prepared using Prism Software (version 4; GraphPad Software, CA). 
Tissue Metabolite Extraction  
All samples were placed in dry ice after retrieval from the í80 °C freezer. Each snap frozen 
tissue was homogenized in 400 µl cold methanol (MeOH) using a homogeniser (IKA®- 
WERKE GmbH & Co., Germany). The homogenate was vortexed for 60 s before being 
centrifuged at 13,000 rpm for 5 min per tissue sample extracted with MeOH (samples extracted 
ZLWK 0H2+ ZHUH VXEVHTXHQWO\ UHIHUUHG WR DV WKH µpolar extracts¶). The supernatant was 
collected using a micropipette syringe and dried in pre-weighed vials in preparation for further 
NMR and MS measurements. Using the same homogenized tissue residue, the process was 
repeated with 400 µl cold dichloromethane (DCM) and centrifuged at 13,000 rpm for 10 min. 
Tissues extracted with DCM were subsequently referred to as the µnon-polar extracts¶. The 
time periods employed for centrifugation were predetermined from preliminary experiments.  
All extracts were freeze-dried and corresponding weights were recorded. 
Bath Fluid Metabolite Extraction 
Each fluid sample was freeze-dried in a freeze drier (Christ Alpha 2-4, SciQuip, UK) and 
weighed. The dried samples were then reconstituted with 500 µl of cold MeOH and vortexed 
for 1 min. The solution was pipetted out and centrifuged as previously described for polar 
extracts. The process was repeated with 600 µl cold DCM on the residue obtained after MeOH 
extraction. The entire extraction procedure was performed under cold conditions with samples 
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placed in dry ice at all times. All samples were freeze-dried as previously described and 
weighed. 
1H-NMR Data Acquisition 
The dried polar extracts were weighed and reconstituted in 200 µl dimethylsulphoxide (DMSO) 
vortexed for 30 s and submitted for 1D 1H-NMR measurements while the DCM extracts (non-
polar extracts) were weighed and reconstituted in 200 µl CDCl3 and similarly submitted for 1D 
1H-NMR measurements. Pre-saturated 1H-NMR experiments were carried out on a JEOL-
LA400 FT-NMR spectrometer system (JEOL Ltd, UK) with an AS400 magnet and measured 
at 400 MHz for 1+XVLQJD3XOVH)LHOG*UDGLHQW³$XWRWXQH´7+$7)*EURDGEDQGKLJK
sensitivity 5 mm probe. Samples were measured in a 3 mm NMR tube with a 5 mm tube 
adapeter. 1H-proton NMR with presaturation of the residual water resonance were obtained 
using the following parameters; 32k data points, spectral width of 5998.4 Hz, acquisition time 
of 2.73 s, relaxation delay of 3.0 s., and pulse width of 5.47 requiring 3.85 min total acquisition 
time.  
HPLC-HRFTMS Data Acquisition 
Extracts of tissues and samples were also submitted for HRMS analysis. Polar extracts were 
reconstituted with 200 µl of 100 % methanol while the non-polar extracts were reconstituted 
in DCM : MeOH at a ratio of 30:70. The 30:70 ratio were predetermined from preliminary 
experiments as best suited for dissolving the non-polar extracts. Details of the HPLC analysis 
can be obtained from the supplementary data.  
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Data Processing and Analysis 
HPLC-HRFTMS Profiles 
The HPLC-HRFTMS metabolic profiles of polar and non-polar extract-treated tissues and 
surrounding bath fluids were analyzed for changes in metabolites before and after drug 
treatment as previously described7. Statistical determination was performed as previously 
described10 in XCMS using the t-test with p < 0.05 considered significant for each pairwise 
comparison of control and treated groups.  Identification of metabolites within XCMS online 
was done using METLIN (a web-based database). Details of the profiling can be obtained from 
the supplementary data. 
Bioinformatic Analysis of HPLC-HRFTMS Data  
The Ingenuity Pathway Analysis (IPA) bioinformatics tool (produced by Ingenuity Systems, 
Redwood City, CA) was used to perform bioinformatic analysis on resulting data. A search 
was additionally performed for regulated pathways with the aid of identified metabolites. 
6WDWLVWLFDO VLJQLILFDQFH ZDV FDOFXODWHG XVLQJ )LVFKHU¶V H[DFW WHVW S was considered 
statistically significant. IPA automatically generates pathways related to specific metabolites 
for a given data set. 
NMR Pre-processing and Analysis 
All NMR data sets were pre-processed using Mnova v. 10.1. The imported spectra were 
manually phased and ELQQHGEHWZHHQį± 10 SSPDWELQYDOXHRIįSSPZLGWK. Residual 
water and solvent peaks were removed. The total spectra area was then normalized to a total 
value of 100 and a 2D matrix (n x d) was created which was then exported into SIMCA.  Mean 
centering was performed before principal component analysis (PCA) and OPLS-DA was 
applied to the datasets.  Potential outliers as well as similarities between the metabolic 
fingerprints was enabled by PCA and this usually occurs in an unsupervised manner. The S-
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line was also used in this study which functions as statistical total correlation spectroscopy 
(STOCSY)13.  
Diagrammatic summary of the methods described above are presented in figure 1. 
 
Results 
Pharmacological analysis 
C3-5 and C6 were observed to decrease uterine contractility (Fig. 2). Data analysis of C3-5 
showed a reduction in the amplitude (p = 0.05), frequency and area under the curve of uterine 
contractions (Fig. 3). Similarly, data analysis of C6 showed a reduction in the amplitude, 
frequency and area under the curve (p < 0.05) of uterine contractions; however, the effect of 
frequency was less marked (Fig. 4).  
HPLC-HRFTMS of Pheophytin and Pheophorbide compounds (C3-5 and C6) 
HRFTMS experiments were analyzed using the multivariate analysis in SIMCA 14.0 and the 
bioinformatics software IPA as previously described10. Multivariate OPLS-DA plots showed 
distinct separations between the control (blue circles) and treated (red circles) groups of C3-5 
(Fig. S1) and C6 (Fig. S2). Multivariate S-plots were also generated which represented every 
metabolite detected within the groups compared. Significantly, regulated metabolites and 
pathways were also displayed as blue in the control and red in the treated (Fig. 5 and 6). Cyclic 
adenosine monophosphate (cAMP), endocannabinoid and catecholamine signaling were 
upregulated while myoinositol (MI) was downregulated (Fig. 5 and 6) in both C3-5 and C6 
treated groups. Other detected metabolites were listed in supplementary tables 1 and 2. These 
metabolites ranged from amino acids to lipids and included an increase in adenosine, cysteinyl 
dopamine, phosphatidyl ethanolamine, glycerolphosphate, phosphatidyl serine, triglycerides, 
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which were observed in the tissues and fluids while a decrease in noradrenaline, tyrosine, and 
phosphatidylinositol were observed in C3-5 treated tissues and fluids (Supplementary Table 
1). For C6 treated groups, an increase in threonine and adenosine were observed in the tissues 
and fluids while a decrease in gamma amino butyric acid (GABA), glutamate, tyrosine, 
methionine, threonine and phenylalanine were detected in the tissues (Supplementary Table 2). 
Metabolites detected in the fluids included an increase in nicotinic acid, uridine 5'-diphospho-
beta-L-threo-pentapyranosyl-4''-ulose (UDP-L-Ara4O), cysteinyldopamine, and ceramide 
while MI, sphingosine, phosphatidylinositol and phosphatidic acid were observed in the bath 
fluids to have been decreased (Supplementary Table 2). 
The IPA bioinformatic software showed cell signaling, lipid metabolism, small 
molecule biochemistry, nucleic and amino acid metabolism as high-level functions associated 
with both C3-5 and C6 mechanisms (Fig. 7 and 8). Canonical pathways generated by IPA 
displayed MI signaling, cytidine diphosphate diacylglycerol (CDP-DAG) and serotonin 
pathways to be associated with the effect of both C3-5 and C6 on uterine contractility (Fig. 7 
and 8). However, nicotinic acid, eicosanoid and GABA pathways were also found associated 
with the effect of C6 on uterine contractility (Fig. 8). 
1H-NMR Analyses of C3-5 and C6 
Multivariate OPLSDA showed distinct separations between the control and treated groups (Fig 
S3 and 4). For C3-5 groups, correlation coefficient plots of the 1H-NMR measurements showed 
Ras homolog gene family, member (RhoA), nucleic acid, and cAMP signaling to be detected 
in the control tissues and bath fluids (Fig. 9) while endocannabinoid and DAG signaling were 
detected in the treated tissues and bath fluids (Fig. 9). For the C6 groups, the correlation 
coefficient plots of the 1H-NMR measurements also indicated the presence of metabolites for 
endocannabinoids signaling in both control and treated groups (Fig. 10). GABA signaling was 
detected in the control while catecholamine and cAMP signaling were detected in the treated 
groups (Fig. 10). Other metabolites detected in C3-4 treated groups included glutamine and 
tyrosine which were detected to have been upregulated in the uterine tissues while anandamide 
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(AEA), glutamate, aspartate, glutamine and phenylalanine were upregulated in the bath fluids 
(Table 2). Arachidonic acid (AA), AEA, MI, DAG, and adenosine triphosphate (ATP) were 
detected to have been downregulated in the uterine tissues, these were similarly observed in 
the bath fluids but in addition GABA, tyrosine, phenylalanine and threonine were 
downregulated (Table 2). In C6-treated groups, other metabolites detected were adenosine, 
glutamate, DAG, adenosine monophosphate, AEA, and aspartate, which were upregulated in 
the tissues while glutamine, ATP and GABA were detected as upregulated in the bath fluids. 
ATP and AA were observed to have been downregulated in the tissues and in the bath fluids 
and in addition MI, DAG, prostaglandin F1, AEA, threonine, were downregulated in the bath 
fluids (Table 3). 
 
Discussion 
The chlorophyll compounds (C3-5 and C6) that affected the contraction of uterine tissue were 
observed to increase the metabolites for the cAMP pathway, as detected by both MS and NMR. 
An increase in myometrial cAMP concentration often results in inhibition of uterine 
contraction. The complete mechanism by which this is achieved appears to be still being 
elucidated14, hence several mechanisms of cAMP-induced relaxation have been proposed. 
Increase cAMP has been reported to activate Na+/Ca2+ pump and promote intracellular storage 
of Ca2+ 15. Recent studies have also suggested that cAMP blocks signal transmission from Ras 
proteins to Raf-1 by interaction with protein kinase A this prevents mitogen activated protein 
kinase (MAPK) activation16,17. An inhibition of phosphoinositol (PI) turnover has also been 
suggested18. 
Myoinositol (MI) signaling was also detected to play a role in the effect of both 
compounds. For instance, MI signaling decreased upon C3-5 and C6 treatment. MI is an isomer 
of cyclohexane-hexol in eukaryotic cells and a precursor of the inositol phospholipids. In 
addition to the well documented pathways for both diacylglycerol (DAG) and IP3 production,  
both acting  as second messengers resulting 19±21, there are several other inositol phospholipid 
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pathways.  These include the complex metabolism of IP3
22, the metabolism of inositol 
polyphosphates23, the novel inositol phospholipid pathway initiated by phosphatidylinositol 3-
kinase which might be regulated by tyrosine kinases24, and the synthesis of 
phosphatidylinositols (PtdIns) glycans25.  The metabolism of inositol phosphate has been 
described as being extremely complex20. In summary, the metabolism of inositol results in the 
generation of several inositol phosphates the commonly known include:  IP3, inositol-1,3,4,5 
phosphate (IP4), inositol-5-phosphate, inositol-3,4,5,6-tetrakisphosphate and inositol-6-
phosphate which have different biologic functions21. IP4  has also been implicated in Ca
2+ 
signaling26,27. Some studies have shown that IP4 may exert both facilitatory and inhibitory 
feedback on calcium signaling as it inhibits IP3 receptors at certain concentrations
28. IP4 has 
been reported to also inhibit IP3 metabolism through IP3 5-phosphatase thus facilitating the 
activation of store operated Ca2+ current (ICRAC). IP4 receptors are located on the nuclear 
membranes, activation of which results in calcium uptake and inhibition of IP3. It has also been 
proposed that IP4 calcium uptake might be mediated through the stimulation of calcium pumps 
29. From the foregoing, MI seems to generate several functional metabolites besides IP3, which 
may play a role in smooth muscle relaxation through inhibition of IP3 or calcium uptake. Based 
on the results from this study, it is therefore proposed that a decrease in IP3 contributed in part 
to the pharmacological effect seen in this study of the chlorophyll compounds C3-5 and C6 on 
myometrial contraction.  
An increase in gamma aminobutyric acid (GABA) signaling was observed with C6 but 
not with C3-5 where a decrease in GABA was observed. GABA and receptor binding sites of 
GABA have been shown to occur in the uterus of rat and rabbit30. GABA has been described 
to activate GABAB to elicit excitatory responses in the rabbit uterus
31 while activation of 
GABAA receptors in the uterus promotes inhibition of uterine contractility and has been 
proposed to play a role in the modulation of uterine contractility30,31. It has also been suggested 
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that the density of the GABA receptor type present in an organ may determine the response 
observed (while the prevailing hormonal environment occurs during pregnancy or during the 
estrous cycle) may determine the type and density of receptors present in the uterus 32±34. 
Catecholamines (adrenaline and noradrenaline) have been reported to contribute to the 
UHJXODWLRQRIP\RPHWULDO FRQWUDFWLRQYLD LQWHUDFWLRQZLWK WKHȕ- DQG Į-adrenergic receptors 
present in the uterus357KHP\RPHWULDO LQKLELWRU\HIIHFWREVHUYHGXSRQDFWLYDWLRQRI WKHȕ-
adrenergic receptors occur through the upregulation of adenylyl cyclase36 while myometrial 
VWLPXODWLRQLVREVHUYHGXSRQDFWLYDWLRQRIĮ-adrenergic receptors through upregulation of the 
*Įq/11 protein and phospholipase C stimulation37,38. In this study, catecholamine synthesis was 
decreased upon treatment of the uterus with the chlorophyll compounds (C3-5 and C6). This 
observation suggested that catecholamines may not play any significant role in the effects of 
ficusphytins on uterine contraction. However, the effect of catecholamines in the regulation of 
spontaneous uterine contraction had to be decreased or inhibited in order for the effect of the 
compounds to be observed. 
The endogenous cannabinoids (endocannabinoids) were also found to be perturbed 
upon treatment of the uterus with ficusphytins. Endocannabinoids were increased on C3-5 
treatment while a decrease was observed upon treatment of uterine tissues with C6. These 
endocannabinoids belong to a class of fatty amides. N-acylethanolamines (NAEs) are 
ethanolamides of long chain fatty acids and exist in various organisms including animals and 
plants39,40. Of these, anandamide (AEA) or N-arachidonoylethanolamide has attracted special 
interest because of its marked biological activities. NAEs are currently considered to be a class 
of endogenous lipid mediators41,42. Upon its identification in 1992 from porcine brain43, AEA 
has so far been the most extensively characterized NAE, which functions as an endogenous 
ligand of cannabinoid receptors and transient receptor potential vanilloid 1 channels and 
actually exerts a variety of central and peripheral activities through these receptors44. Like the 
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pharmacologically active compounds in cannabis (Cannabis sativa), its effects is exerted 
through binding to and activating specific cannabinoid receptors (CBR) and along with 2-
arachidonoyl-glycerol AEA45. Both cannabinoid receptors CB1 and CB2 are membrane-bound 
G-protein coupled receptors46. CB1 is mainly found in the central nervous system
47 but has also 
been found in organs such as the heart, uterus, testis and small intestine, while the CB2 receptor 
is found primarily in the spleen and other cells associated with immunochemical functions, as 
well as some peripheral cells48. Endocannabinoids have been found in the uterus with one of 
the highest levels detected in the mouse uterus49 and has also been implicated in the regulation 
of the female reproductive cycle especially with the presence of cannabinoid receptors in the 
uterus50. There have been a couple of investigations into the effects of endocannabinoids on 
uterine contractions. However, there are also contradictory reports on the effect of 
endocannabinoids on uterine contractility. Dennedy et al. reported a relaxant effect of AEA on 
uterine contractility and demonstrated that this relaxant effect may be linked to a reduction in 
uterine prostaglandin synthesis51. In contrast, an increase in the force of spontaneous uterine 
contraction was reported for the endocannabinoids52, which was purportedly due partly to a 
cannabinoid-induced production of PGE2 and PGFĮ resulting in a decrease in the intracellular 
concentration of cAMP53. Similarly, some seemingly contradictory reports on the mechanisms 
of action of endocannabinoids exist. Some researchers report on a direct regulation of uterine 
contraction via binding with CB1 and CB2 receptors that preferentially couple to inhibitory GĮLR
proteins to inhibit adenylate cyclase activity, and consequently reduce intracellular cAMP 
levels 54. Yet some researchers report on an observed increase in cAMP levels following CB1 
activation55, suggesting a possible coupling WR*Įs of the G protein receptors. Other signaling 
events, including increased activity of  MAPK, inhibition of voltage-gated Ca2+ channels, 
activation of K+ channels, and nitric oxide (NO) generation, have also been suggested to follow 
CB receptor subtypes activation under different conditions53. It may seem therefore, that 
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binding of endocannabinoids to their receptors can result in activation/regulation of a number 
of signal transduction pathways, which are dependent on the agonist involved and the factors 
in place upon binding. Briefly, binding can result in inhibition of Ca2+ channels; inhibition of 
adenylyl cyclase and corresponding decrease of cAMP-dependent protein kinase, which leads 
to decreased phosphorylation of the K+ channels and regulation of ionic currents; activation of 
focal adhesion kinase and activation of MAPK cascades56 that includes extracellular signal-
regulated kinases (ERK) p38 MAPK cascades57,58, as well as the stimulation of other 
intracellular pathways such as the phosphatidylinositol 3-kinase (PI3K)/Akt (also known as 
Protein Kinase B (PKB)) pathway through CB2
59. Akt is a serine/threonine-specific protein 
kinase that plays a key role in multiple cellular processes60.  Different subtypes of Akt exist but 
Akt1 is involved in the PI3K/AKT/mTOR pathway and other signaling pathways
61. Activation 
RI*35³&%3´FDQQDELQRLGUHFHSWRUKDVEHHQOLQNHGWRDQLQFUHDVHLQLQWUDFHOOXODU&D2+ 
increase62; activation of the small GTPase proteins RhoA, Rac, and Cdc42 63,64; and ERK 
phosphorylation65,66. It has also been observed that muscarinic and glutamate receptors have 
allosteric sites for AEA binding67. It can therefore be seen that endocannabinoids exert a highly 
complex network of interactions68, which may probably extend its role in modulating uterine 
contractions as well its role in the mechanism of uterine activity of the ficusphytins in this 
study. 
Dopamine was also detected to contribute to the effects of Ficus fractions on uterine 
contractions. Uterine contraction increased on C3-5 treatment. Dopamine has been reported to 
inhibit uterine contractions in the non-pregnant uterus via action on adrenergic receptors69,70. 
However, at early and term pregnancy, dopamine has been reported to stimulate myometrial 
contractility71±73. Dopamine can oftentimes exert different and opposing effects on organs or 
tissues and this observation has been associated with the species involved as well as the 
receptors present since dopamine is known to act on both dopaminergic and adrenergic 
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receptors70. Endogenous dopamine has been previously detected in the uterus74. Interestingly 
in this study, while catecholamine synthesis decreased, dopamine signaling increased. It was 
also observed that in each case where dopamine was increased, endocannabinoids signaling 
was also increased simultaneously. It is therefore possible that the increased dopamine detected 
in this study is a product of the AEA pathway. N-arachidonyldopamine (NADA) has been 
detected as an endogenous component of certain mammalian tissues75. NADA binds to the CB1 
receptor and transient receptor potential vanilloid type 1 (TRPV1) channels and regulates 
calcium mobilization76. Biosynthesis is believed to occur mainly by conjugation of dopamine 
with arachidonic acid, catalyzed by a fatty acid amide hydrolase (not via the CoA ester), 
although there are suggestions that some might be derived from arachidonoyltyrosine77,78. 
Studies have shown the inhibition of T-type Ca2+ channels by NADA79 and sarcoendoplasmic 
reticulum calcium transport ATPase (SERCA) uncoupling80. Unfortunately, it would appear 
that not many studies have been done on the relationship between NADA and uterine 
contractility. 
RhoA signaling was also detected in this study. A decrease was detected on treatment 
with C3-5. The role of the small G protein rhoA (a member of the Rho subfamily of the Ras 
superfamily of monomeric GTPases) in the regulation of myometrial contractility has recently 
received considerable attention. Small G protein rhoA  has been described to be involved in 
agonist-induced Ca2+-sensitization by acting downstream on receptor occupancy81 as it has 
been shown to increase myosin light chain (MLC) phosphorylation at a constant Ca2+ 
concentration82. Inactivation of rhoA therefore would inhibit Ca2+-sensitization. An effector 
molecule rho-associated kinase (ROK) appears to play a role in the Ca2+-sensitizing effects of 
rhoA activation83. ROK inhibits the activity of myosin phosphatase84,85 through the inhibition 
of myosin binding subunits86. Activation of certain receptors in the myometrium results in the 
translocation of rhoA from the cytoplasm to the cell membranes as was reported to occur with 
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muscarinic receptors87. RhoA and ROK have been shown to be involved in oxytocin-induced 
myometrial contractility86. Caveolins have also been shown to regulate the activities of rhoA 
and probably ROK87. Thus, a reduction in rhoA would result in the inhibition of myometrial 
contractility.  
 Extracellular signal-related kinases (ERK) signaling was detected in this study to have 
been increased on C3-5 treatment of uterine smooth muscle but a decrease was observed with 
C6. The involvement of the ERK pathway has been proposed to play a role in the regulation 
of agonist-induced smooth muscle contraction, activation of which has been shown to stimulate 
contraction 88±91. ERK also seems to be involved in spontaneous uterine contractility 92 (Li et 
al., 2003). However, it has been proposed that the ERK pathway may not affect Ca2+ channels 
directly 93. ERK pathway has been shown to be involved in OT-induced uterine contraction 14 
as well as prostaglandin FĮ ± induced uterine contraction94 and has been proposed to exert its 
effect by phosphorylation of caldesmon (CAD)88. Therefore, activation of ERK would lead to 
an increase in contraction as exhibited with C3-5 and a decrease in ERK would lead to 
inhibition of uterine contractility as observed with C6. 
 The idea of cross talk between signaling pathways is currently being investigated by 
several scientists particularly as relates to G-proteins and their second messenger pathways. 
For instance stimulation of the CB1 cannabinoid receptor has been shown to lead to an increase 
in dopamine turnover95,96 while the stimulation of D2 receptors leads to an increase in the 
endocannbinoid AEA97. Activation of either CB1 or D2 receptors results in the inhibition of 
adenylyl cyclase, however simultaneous stimulation of both receptors appears to lead to the 
accumulation and increase in cAMP, and ERK receptor activation98 suggesting the presence of 
associated signaling pathways regulated when both receptors are activated by agonists98,99. 
Increase in cAMP has also been reported to induce an increase in cGMP-dependent protein 
kinase which further potentiates relaxation of smooth muscles 100 and inhibits rhoA signaling 
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pathway 101,102. Therefore, crosstalk between receptors may have played a role in the effects of 
pheophytins in this study considering the varying metabolites significantly regulated on 
treatment of the uterine tissues. A comprehensive list of significant metabolites detected by the 
NMR analysis is shown in supplementary table 3. 
Conclusion 
The cholorophyll compounds in fraction C3-5, acted primarily by its interaction with cAMP, 
dopamine, ERK1/2 and glutamate. Possible connection with other catecholamines, 
prostanoids, MI, RhoA and GABA was also suggested. While the chlorophyll compounds in 
fraction C6 acted primarily by its interaction with cAMP, sphingosine, glutamate and GABA. 
Possible connection with catecholamines, endocannabinoids, ERK1/2, RhoA, DAG and MI 
was also postulated. An in-depth understanding of signal transduction pathways discovered 
from this study could therefore provide a significant aid in the design of compounds such as 
those isolated from F. exasperata and might prove useful in the treatment and prevention of 
uterine disorders. 
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Figure Legends 
Figure 1. Flow chart depicting the pharmacological and metabolomic analysis processes.  
Figure 2. Original recordings showing the effect of C3-5 and C6 on the isolated mouse uterus. 
Panel A shows C3-5 on uterine contractions while panel B shows C6 on uterine contractions. 
Figure 3. Bar graphs showing the data analysis of C3-5 on uterine contractility. C3-5 inhibited 
the amplitude (A), and the frequency (B) of uterine contraction. An overall inhibitory activity 
was observed as shown in the area under the curve analysis (AUC) (C). n= 4 animals, *p 
0.05. 
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Figure 4. Bar graphs representing data analysis of C6 on mouse uterine contractility. C6 was 
shown to inhibit the amplitude (A) and shown to produce a slight inhibition of the frequency 
(B) of uterine contraction. Overall, an inhibitory effect of C6 was observed as depicted in the 
area under the curve (AUC) (C). Q DQLPDOVS 
Figure 5. OPLS-DA S plots of polar (A and B) and non-polar (C and D) C3-5-treated groups.  
A and B shows the S plots for treated uterine tissues, while C and D shows the S plots generated 
for the bath fluids. All metabolites detected are shown in green circles. Significantly, regulated 
metabolites of the control groups are presented in blue while those of the treated groups are 
presented in red with the corresponding m/z values.  = cAMP signaling; = endocannabinoid 
signaling;  = amino acid (aa) metabolism;  = DAG signaling;  = catecholamine synthesis; 
 = MI biosynthesis/signaling. n = 4 animals 
Figure 6. OPLS-DA S plots of polar (A and B) and non-polar (C and D) C6-treated groups.  A 
and B shows the S plots for treated uterine tissues, while C and D shows the S plots generated 
for the bath fluids. All metabolites detected are shown in green circles. Significantly, regulated 
metabolites of the control groups are presented in blue while those of the treated groups are 
presented in red with corresponding m/z values.  = cAMP signaling; = endocannabinoid 
signaling;  = DAG signaling;  = catecholamine synthesis;  = MI biosynthesis/signaling; 
 = dopamine metabolism. n = 4 animals 
 
Figure 7. Bar charts displaying top functions (A and B) and canonical pathways (C and D) 
extracted by IPA software for metabolites obtained from C3-5-treated uterine tissues and bath 
fluids. The high-level functional categories associated with C3-5- treated groups are displayed 
along the x-axis in A and B above while high-level canonical pathways are shown in C and D. 
The y-axis in A and B displays the -(log) significance.  Taller bars in A are more significant 
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than the shorter bars. Functions are listed from most significant to least and the orange 
horizontal line in A and B denotes the cut-off for significance (p = 0.05). 
Figure 8. Bar charts displaying top functions (A and B) and canonical pathways (C and D) 
extracted by IPA software for metabolites obtained from C6-treated uterine tissues and bath 
fluids. The high level functional categories associated with C6- treated groups are displayed 
along the x-axis in A and B above while high level canonical pathways are shown in C and D. 
The y-axis in A and B displays the -(log) significance.  Taller bars in A are more significant 
than the shorter bars. Functions are listed from most significant to least and the orange 
horizontal line in A and B denotes the cut-off for significance (p = 0.05). 
Figure 9 Correlation coefficient plots showing the distribution of metabolites in the NMR 
spectra of the polar (A and B) and non-polar C3-5-treated groups. Plot of NMR data for tissues 
are in A and B while plots for those associated with the bath fluids are in C and D.  The blue 
columns represent the control groups and the red columns represent the treated groups. 
Significant metabolites have been highlighted and represented according to the corresponding 
pathways.  = cAMP signaling;  = endocannabinoid signaling;  = DAG signaling/lipid 
metabolism;  = NA metabolism;   = MI biosynthesis/signalling;  = RhoA signaling;  = 
catecholamine signaling;  = GABA signaling. These pathways were found to be strongly 
correlated with the activity of C3-4. n= 4 animals. 
Figure 10. Correlation coefficient plots showing the distribution of metabolites in the NMR 
spectra of the polar (A and B) and non-polar C6-treated groups. Plot of NMR data for tissues 
are in A and B while plots for those associated with the bath fluids are in C and D.  The blue 
columns represent the control groups and the red columns represent the treated groups. 
Significant metabolites have been highlighted and represented according to the corresponding 
pathways.  = cAMP signaling;  = endocannabinoid signaling;  = DAG signaling/lipid 
metabolism;  = NA metabolism;   = MI biosynthesis/signaling;  = RhoA signaling;  = 
catecholamine signaling;  = GABA signaling. These pathways were found to be strongly 
correlated with the activity of C8. n= 4 animals. 
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Table 1. Summary of Pathways and Metabolites detected by HR-FTLCMS on Effect of 
Pheophytins and Pheophorbides (C3-5 and C6) of F. exasperata on Uterine Contractility 
FC= Fold change; GABA = gamma aminobutyric acid; cAMP= cyclic adenosine monophosphate; MI= 
myoinositol; DAG = Diacylglycerol; PI= Phosphatidylinositol; m/z = mass to charge ratio; Rt = 
Retention time; nd = not detected 
Pathway 
  
Metabolome 
  
Adduct 
  
m/z 
  
Rt 
  
C6 C3-5 
Tissues Fluids Tissues Fluids 
GABA Receptor Signaling GABA [M+H]+ 118.0863 1.36 1.365 -1.9603  nd  nd 
GABA Receptor Signaling Glutamate [M+H]+ 148.0606 1.37 -1.6216  nd  nd  nd 
cAMP Metabolism 8-Azaadenosine [M+2Na]2+ 157.0353 1.41  nd  nd 11433.3826 9785.7196 
157.0353 1.48 498.8266 1393.879  nd  nd 
MI Biosynthesis MI [M+Na]+ 
  
203.0527 1.57  nd -1.498  nd -1.3952 
Catecholamine Synthesis L-Tyrosine [M+2H+Na]3+ 110.0201 3.66 1.47941  nd  nd  nd 
110.0201 4.55  nd  nd  nd -1.7568 
Endocannabinoid Metabolism Oleoylethanolamide [M+H-2H2O]
+ 304.2999 19.71 -24.8789 -1.2906  nd  nd 
DAG 
Metabolism/Endocannabinoid 
Signaling 
N- arachidonoyl 
amine 
[M+NH4]
+ 504.3241 23.38  nd  nd  nd 7.3176 
MI Biosynthesis PI(17:1/22:2) [M+H-H2O]
+ 885.5897 32.42  nd  nd  nd -6.7596 
MI Biosynthesis PI(O-16:0/20:2) [M+H-2H2O]
+ 813.5683 34.29  nd -120.925  nd  nd 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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Table 2. Summary of the Proposed Mechanism(s) of Action of C3-5 of Ficus exasperata 
Leaves Determined from Metabolomic Analysis 
GABA = gamma aminobutyric acid; cAMP = cyclic adenosine monophosphate; MI = myoinositol; DAG = diacylglycerol; ERK = extracellular signal 
regulated kinase; RhoA = Ras homolog gene family member A; nd = not detected; 伴 = increase; 判 = decrease 
 
Extract/ 
Fraction 
Active 
Compound 
(s) 
Uterine Smooth 
Muscle Activity 
MS Metabolomic Pathways NMR Metabolomic Pathways 
C3-5 Pheophytin 
a series 
Inhibition/Contraction Uterine Tissues Bath Fluids Uterine Tissues Bath Fluids 
cAMP signaling伴 cAMP signaling伴 nd cAMP signaling伴 
Dopamine signaling伴 nd nd nd 
 MI signaling判 MI signaling判 nd 
Catecholamine 
synthesis判 
Catecholamine 
synthesis判 
Catecholamine 
synthesis判 
Catecholamine 
synthesis判 
nd Endocannabinoid 
signaling伴 
Endocannabinoid 
signaling伴 
Endocannabinoid 
signaling伴判 
nd nd RhoA signaling伴判 RhoA signaling判 
Prostanoid signaling判 Prostanoid signaling判 Prostanoid signaling判 Prostanoid signaling判 
nd nd nd nd 
nd nd DAG signaling判 DAG signaling判 
nd nd nd GABA signaling判 
nd nd ERK1/2 signaling伴 ERK1/2 signaling伴 
nd nd Glutamate signaling伴 Glutamate signaling伴 
 
 
 
 
 
 
 
 
 
Table 3 Summary of the Proposed Mechanism(s) of Action of C6 of Ficus exasperata 
Leaves Determined from Metabolomic Analysis 
GABA = gamma aminobutyric acid; cAMP = cyclic adenosine monophosphate; MI = myoinositol; DAG = 
diacylglycerol; ERK = extracellular signal regulated kinase; RhoA = Ras homolog gene family member A; nd 
= not detected; 伴 = increase; 判 = decrease 
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Extract/ 
Fraction 
Active 
Compound 
(s) 
Uterine 
Smooth 
Muscle 
Activity 
MS Metabolomic Pathways NMR Metabolomic Pathways 
   Uterine 
Tissues 
Bath Fluids Uterine 
Tissues 
Bath Fluids 
C6 Pheophytin 
series 
Inhibition nd Sphingosine 
signaling伴 
nd nd 
GABA 
signaling判 
nd nd GABA 
signaling伴 
cAMP 
signaling伴 
cAMP 
signaling伴 
nd nd 
Catecholami
ne synthesis判 
Catecholamine 
synthesis判 
nd Catecholamine 
synthesis判 
Glutamate 
metabolism判 
nd nd nd 
Endocannabi
noid 
signaling判 
Endocannabin
oid signaling判 
Endocannabin
oid signaling判 
Endocannabin
oid signaling判 
nd MI signaling判 nd MI signaling判 
nd nd nd DAG 
signaling判 
nd nd Glutamate 
signaling伴 
Glutamate 
signaling伴 
nd nd ERK1/2 
signalling判 
nd 
nd nd RhoA 
signaling判 
RhoA 
signaling判 
 
 
 
 
 
 
 
 
